$6.99
0.152.19%
At Close: -
$6.99
00.00%
After Hours: 1:00 PM EDT
15 minutes delayed
Maravai LifeSciences
MRVINASDAQ
Maravai LifeSciences (NASDAQ:MRVI) Stock, Analyst Ratings, Price Targets, Predictions
Maravai LifeSciences Holdings Inc has a consensus price target of $16, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from Baird, Craig-Hallum, and RBC Capital on May 9, 2024, April 10, 2024, and February 23, 2024. With an average price target of $13 between Baird, Craig-Hallum, and RBC Capital, there's an implied 85.98% upside for Maravai LifeSciences Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Baird
Craig-Hallum
RBC Capital
Stifel
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Maravai LifeSciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2024 | Buy Now | 43.06% | Baird | Catherine Schulte | $8 → $10 | Maintains | Outperform | Get Alert |
| 04/10/2024 | Buy Now | 114.59% | Craig-Hallum | Christian Schwab | → $15 | Initiates | → Buy | Get Alert |
| 02/23/2024 | Buy Now | 100.29% | RBC Capital | Conor McNamara | $12 → $14 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | 43.06% | Stifel | Daniel Arias | $11 → $10 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 14.45% | B of A Securities | Michael Ryskin | $10 → $8 | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2023 | Buy Now | 0.14% | Goldman Sachs | Matthew Sykes | $8 → $7 | Maintains | Neutral | Get Alert |
| 11/09/2023 | Buy Now | 57.37% | Morgan Stanley | Tejas Savant | $12 → $11 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 71.67% | Morgan Stanley | Tejas Savant | $27 → $12 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 143.2% | Deutsche Bank | Justin Bowers | $23 → $17 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 157.51% | RBC Capital | Conor McNamara | $20 → $18 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 14.45% | Goldman Sachs | Matthew Sykes | $12 → $8 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 57.37% | Baird | Catherine Schulte | $18 → $11 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 57.37% | Credit Suisse | Dan Leonard | $14 → $11 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | — | Keybanc | Paul Knight | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 05/23/2023 | Buy Now | 100.29% | Credit Suisse | Dan Leonard | $18 → $14 | Downgrade | Outperform → Neutral | Get Alert |
| 05/10/2023 | Buy Now | 85.98% | Goldman Sachs | Matthew Sykes | $16 → $13 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | 286.27% | Morgan Stanley | Tejas Savant | $29 → $27 | Maintains | Overweight | Get Alert |
| 05/09/2023 | Buy Now | 186.12% | RBC Capital | Conor McNamara | $22 → $20 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 85.98% | Goldman Sachs | Matthew Sykes | $16 → $13 | Downgrade | Buy → Neutral | Get Alert |
| 05/09/2023 | Buy Now | 229.04% | Deutsche Bank | Justin Bowers | $25 → $23 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 157.51% | Credit Suisse | Dan Leonard | $23 → $18 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 314.88% | Morgan Stanley | Tejas Savant | $32 → $29 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | 214.74% | Baird | Catherine Schulte | $25 → $22 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 229.04% | Credit Suisse | Dan Leonard | $26 → $23 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 243.35% | Keybanc | Paul Knight | $28 → $24 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | 128.9% | Goldman Sachs | Matthew Sykes | $18 → $16 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 128.9% | UBS | Dan Brennan | $20 → $16 | Downgrade | Buy → Neutral | Get Alert |
| 12/14/2022 | Buy Now | 257.65% | Deutsche Bank | Justin Bowers | → $25 | Initiates | → Buy | Get Alert |
| 12/07/2022 | Buy Now | 214.74% | RBC Capital | Conor McNamara | → $22 | Initiates | → Outperform | Get Alert |
| 11/04/2022 | Buy Now | 157.51% | Goldman Sachs | Matthew Sykes | $30 → $18 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 357.8% | Morgan Stanley | Tejas Savant | $35 → $32 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 143.2% | B of A Securities | Michael Ryskin | $32 → $17 | Downgrade | Buy → Neutral | Get Alert |
| 11/03/2022 | Buy Now | 271.96% | Credit Suisse | Dan Leonard | $34 → $26 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 300.57% | Keybanc | Paul Knight | $35 → $28 | Maintains | Overweight | Get Alert |
| 08/25/2022 | Buy Now | 386.41% | Credit Suisse | Dan Leonard | → $34 | Initiates | → Outperform | Get Alert |
| 08/08/2022 | Buy Now | 400.72% | Morgan Stanley | Tejas Savant | $49 → $35 | Maintains | Overweight | Get Alert |
| 07/14/2022 | Buy Now | 400.72% | Goldman Sachs | — | $44 → $35 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 601% | Morgan Stanley | Tejas Savant | $54 → $49 | Maintains | Overweight | Get Alert |
| 05/06/2022 | Buy Now | 601% | Keybanc | Paul Knight | $58 → $49 | Maintains | Overweight | Get Alert |
| 02/25/2022 | Buy Now | 672.53% | Morgan Stanley | Tejas Savant | $59 → $54 | Maintains | Overweight | Get Alert |
| 08/12/2021 | Buy Now | 786.98% | Morgan Stanley | Tejas Savant | — | Maintains | Overweight | Get Alert |
| 08/11/2021 | Buy Now | 672.53% | Credit Suisse | Katie Tryhane | — | Maintains | Outperform | Get Alert |
| 08/11/2021 | Buy Now | 729.76% | Keybanc | Paul Knight | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Maravai LifeSciences (MRVI) stock?
The latest price target for Maravai LifeSciences (NASDAQ:MRVI) was reported by Baird on May 9, 2024. The analyst firm set a price target for $10.00 expecting MRVI to rise to within 12 months (a possible 43.06% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Maravai LifeSciences (MRVI)?
The latest analyst rating for Maravai LifeSciences (NASDAQ:MRVI) was provided by Baird, and Maravai LifeSciences maintained their outperform rating.
When was the last upgrade for Maravai LifeSciences (MRVI)?
The last upgrade for Maravai LifeSciences Holdings Inc happened on December 12, 2023 when B of A Securities raised their price target to $8. B of A Securities previously had a neutral for Maravai LifeSciences Holdings Inc.
When was the last downgrade for Maravai LifeSciences (MRVI)?
The last downgrade for Maravai LifeSciences Holdings Inc happened on August 8, 2023 when Keybanc changed their price target from N/A to N/A for Maravai LifeSciences Holdings Inc.
When is the next analyst rating going to be posted or updated for Maravai LifeSciences (MRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maravai LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maravai LifeSciences was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
Is the Analyst Rating Maravai LifeSciences (MRVI) correct?
While ratings are subjective and will change, the latest Maravai LifeSciences (MRVI) rating was a maintained with a price target of $8.00 to $10.00. The current price Maravai LifeSciences (MRVI) is trading at is $6.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.